

Claims

1. A method of treating conditions associated with pain and alleviating the symptoms associated therewith which comprises administering to a mammal, including man, a vanilloid VR-1 antagonist or a pharmaceutically acceptable derivative thereof and an NSAID or a pharmaceutically acceptable derivative thereof, wherein said VR-1 antagonist or said NSAID may optionally be administered as a sub-maximal amount.
2. A method according to claim 1, wherein said VR-1 antagonist or said NSAID is administered as a sub-maximal amount.
3. A method according to claim 1 or claim 2, wherein said NSAID is a COX-2 inhibitor or a pharmaceutically acceptable derivative thereof.
4. A method according to claim 3, wherein the COX-2 inhibitor is selected from 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine, CDC-501, celecoxib, COX-189, 4-(2-oxo-3-phenyl-2,3-dihydrooxazol-4-yl)benzenesulfonamide, CS-179, CS-502, D-1367, darbufelone, DFP, DRF-4367, etodolac, flosulide, JTE-522 (4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluorobenzenesulfonamide), L-745337, L-768277, L-776967, L-783003, L-791456, L-804600, meloxicam, MK663 (etoricoxib), nimesulide, NS-398, parecoxib, 1-Methylsulfonyl-4-(1,1-dimethyl-4-(4-fluorophenyl)cyclopenta-2,4-dien-3-yl)benzene, 4-(1,5-Dihydro-6-fluoro-7-methoxy-3-(trifluoromethyl)-(2)-benzothiopyran o(4,3-c)pyrazol-1-yl)benzenesulfonamide, 4,4-dimethyl-2-phenyl-3-(4-methylsulfonyl)phenyl)cyclobutenone, 4-Amino-N-(4-(2-fluoro-5-trifluoromethyl)-thiazol-2-yl)-benzene sulfonamide, 1-(7-tert-butyl-2,3-dihydro-3,3-dimethyl-5-benzo-furanyl)-4-cyclopropyl butan-1-one, Pharmaprojects No.6089 (Kotobuki Pharmaceutical), rofecoxib, RS-113472, RWJ-63556, S-2474, S-33516, SC-299, SC-5755, valdecoxib, UR-8877, UR-8813, UR-8880 or a physiologically acceptable salt or solvate thereof.

5. A method according to claim 3, wherein the COX-2 inhibitor is selected from celecoxib, rofecoxib, valdecoxib, parecoxib, 4-(4-cyclohexyl-2-methyl-5-oxazolyl)-2-fluorobenzenesulfonamide (JTE-522) and 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine or physiologically acceptable salt or solvate thereof.
6. A method according to claim 5, wherein the COX-2 inhibitor is 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine or a physiologically acceptable salt or solvate thereof.
7. A method according to claim 5, wherein the COX-2 inhibitor is rofecoxib or a physiologically acceptable salt or solvate thereof.
8. A method according to any preceding claim, wherein the vanilloid receptor (VR-1) antagonist is selected from those compounds disclosed GB Patent Applications GB 0303464.2, GB 0305291.7, GB 0305290.9, GB 0305165.3, GB 0305426.9, GB 0305285.9, GB 0305163.8 and GB 0316554.5; International Patent Application Number PCT/EP03/10262; and International Patent Applications WO 02/072536, WO 02/090326, WO 03/022809, WO 03/053945 and WO 03/068749, WO 02/08221, WO 03/062209, WO 02/16317, WO 02/16318, WO 02/16319, WO 02/30956, WO 02/076946, WO 03/049702, WO 03/070247, WO 03/066595, WO 03/074520, WO 03/014064, WO 03/055484, WO 03/095420 and WO 03/080578.
9. A method according to claim 8, wherein the vanilloid receptor (VR-1) antagonist is (2R)-4-(3-chloropyridin-2-yl)-2-methyl-N-[4-trifluoromethylphenyl]piperazine-1-carboxamide or N-(2-Bromophenyl)-N'-[[(R)-1-(5-trifluoromethyl-2-pyridyl)pyrrolidin-3-yl]]urea or or a physiologically acceptable salt or solvate thereof.
10. A method according to claim 1, wherein the VR-1 antagonist is N-(2-Bromophenyl)-N'-[[(R)-1-(5-trifluoromethyl-2-pyridyl)pyrrolidin-3-yl]] or a pharmaceutically acceptable derivative thereof and the NSAID is 2-(4-ethoxy-

phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine or a pharmaceutically acceptable derivative thereof.

11. A method according to claim 1, wherein the VR-1 antagonist is *N*-(2-Bromophenyl)-*N'*-[*((R)*-1-(5-trifluoromethyl-2-pyridyl)pyrrolidin-3-yl)] or a pharmaceutically acceptable derivative thereof and the NSAID is rofecoxib or a pharmaceutically acceptable derivative thereof.
12. A pharmaceutical composition which comprises a vanilloid VR-1 antagonist or a pharmaceutically acceptable derivative thereof, an NSAID or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier therefor, with the proviso that said VR-1 antagonist is not a compound disclosed in International Patent Application, Publication Number WO 02/076946.